Arvinas, Inc. Profile Avatar - Palmy Investing

Arvinas, Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera…

Biotechnology
US, New Haven [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Arvinas, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Arvinas, Inc. can't present revenue by segment

End of ARVN's Analysis
CIK: 1655759 CUSIP: 04335A105 ISIN: US04335A1051 LEI: - UEI: -
Secondary Listings
ARVN has no secondary listings inside our databases.